Cancer Center and Emily Herrmann

Researchers at Houston Methodist may have hit a breakthrough recently as they discovered a combination treatment that significantly improves the chances that a patient’s drug-resistant triple-negative breast cancer will respond positively to the treatment. The research team, led by Dr. Jenny Chang, director of the Cancer Center and Emily Herrmann Presidential Distinguished Chair in Cancer